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A B S T R A C T
For the first time the method DI-SPME/LC-TOFMS was used and developed in order to determine the large
antidepressant drugs in real forensic cases. The aim of the study was to optimize the new DI-SPME/LC-TOFMS
method for the quantification of the large group of psychotropic drugs such as benzodiazepines, selective ser-
otonin reuptake inhibitors, selective serotonin and noradrenaline reuptake inhibitors, tricyclic antidepressants
and sleeping pills “Z". The volume of the sample, adsorption time, post-adsorption purification and desorption
time were precisely optimized. The validation parameters such as limit of detection and quantification, linearity,
precision during and between days and the matrix effect were determined. All obtained values are within the
acceptable range for toxicological analyses. The usefulness of the method was confirmed by analyzing the post-
mortem samples. Drug concentrations were determined in real samples with high precision, which gives per-
spectives for the DI-SPME/LC-TOFMS routine application in toxicological and forensic analyses in the future.
1. Introduction
Due to complicated post-mortem processes that occur in the body
after intake of drugs or poisons like redistribution, degradation, and
contamination, it is necessary to provide a complex analysis of available
body fluids like urine, blood or other alternative materials such as bone
marrow. Material which can be helpful in post-mortem investigation is
bone marrow aspirate (BMA), which is a semi-liquid form (it can be
handled with a pipette) of bone marrow, placed inside the bones [1–3].
However, analysis of alternative materials often carried out with var-
ious limitations and compared to that analysis of BMA appears to have
few practical advantages. It is a well-preserved post-mortem material,
because of the physical barrier provided by cortical bone, which can be
easily collected in large amounts and may be used as an alternative
material to peripheral venous blood [4–6]. Due to high fat level and
blood supply, it is possible to determine psychotropic drugs in bone
marrow, which has been confirmed by Snamina et al. [7] with very
satisfying results. On the other hand Cartiser et al. [2] provided a
comprehensive summary on correlation studies between blood or
plasma and bone marrow levels of different xenobiotics. The correla-
tions varied from very low to almost absolute, depending on the drug.
The success and application of the method often depend on its
capabilities, trueness and also time of whole analysis. Considering ex-
traction of analytes as the most demanding, time-consuming and multi-
step process it is regarded as a critical process to carry out in the whole
analysis. The technique which may facilitate and simplify the extraction
of analytes from complex samples like biological materials may be
Direct Immersion Solid-Phase Micro Extraction (DI-SPME) [8–10]. It is
an extraction technique based on the sorption of analytes on the sta-
tionary phase of fused silica, placed on the solid support. The DI-SPME
procedure is based on the exposure of the fiber to the sample for suf-
ficient time. This technique integrates extraction, concentration and
analyte desorption into a single procedure [11,12]. As the technique is
reducing sample handling, solvent use, time and cost it is prosperous for
toxicological and forensic analysis. Due to the wide selection of fiber
coatings and its sorption capabilities DI-SPME extraction is also used in
food and environmental analyses, as well as studies for its in vivo ap-
plication are carried out. The initial application of the DI-SPME tech-
nique in drug analysis was for psychotropic substances. Moreover, in
recent years the increase of DI-SPME applications was observed with
connection of liquid chromatography and capillary electrophoresis
[13,14].
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The aim of the studies was to present the first time the application of
newly developed DI-SPME/LC-TOFMS method for the detection and
quantification of a large group of psychotropic drugs and its metabolites
in the post-mortem biological matrix. The matter of analysis were very
often misused antidepressants from groups like Benzodiazepines
(BZDs), Selective Serotonin Reuptake Inhibitors (SSRI's), Serotonin and
Norepinephrine Reuptake Inhibitors (SNRI's) and Tricyclic
Antidepressants (TCA's). The post-mortem biological materials which
were evaluated in this study were: human blood and bone marrow
aspirate. In the article, the final protocol for the optimized extraction
process was formulated. As the developed method does not require
modification of the matrix, it is an additional advantage, which
shortens and simplifies the whole process. Crucial parameters that were
optimized were sample volume, time of adsorption, post-adsorption
washing and time of desorption. Once optimized, the method was
evaluated by determination of validation parameters and used for the
analysis of forensic case samples.
2. Experimental
2.1. Chemicals and reagents
Drug standards of the analytes: alprazolam (ALP), amitriptyline
(AMI), bromazepam (BRO), carbamazepine (CBZ), citalopram (CIT),
clonazepam (CLO), clorazepate (CLOR), desipramine (DESI), diazepam
(DIA), estazolam (EST), flunitrazepam (FLUN), fluoxetine (FLUOX),
imipramine (IMI), lorazepam (LOR), lormetazepam (LORM), mid-
azolam (MID), nitrazepam (NITR), nordazepam (NORD), nortriptyline
(NORT), paroxetine (PAROX), prazepam (PRA), temazepam (TEM),
tetrazepam (TETRA), venlafaxine (VEN), zolpidem (ZOL) were pur-
chased from Lipomed AG (Arlesheim, Switzerland). The deuterated
analogues of drugs: alprazolam-d5, bromazepam-d5, diazepam-d5,
lorazepam-d4, lormetazepam-d3, midazolam-d4, nitrazepam-d5, te-
mazepam-d5, venlafaxine-d6, zolpidem-d6 were also purchased from
Lipomed AG (Arlesheim, Switzerland). The LC-MS grade chromato-
graphic solvents acetonitrile, methanol, isopropyl alcohol, and sodium
hydroxide were obtained from Fluka Analytical (Seelze, Germany).
Analytical grade ammonium formate was purchased from Sigma-
Aldrich (St. Louis, MA, USA), analytical grade formic acid was pur-
chased from Merck (Darmstadt, Germany). Finally, the deionized ul-
trapure water (18.2MΩ ⋅ cm, TOC < 5 ppb) was obtained and filtered
through a Mili-Q Plus system (Milipore, Bedford, Ma, USA).
For the analyses following devices were utilized. The HPLC vials
(1.5 mL) and inserts (200 μL) were purchased from VWR (Randor, PA,
USA). The SPME-LC Probe 45 μm C18-Silica fibers (Supelco) were
purchased from Merck (Darmstadt, Germany). Fibers condition were
monitored with use of Scanning Electron Microscope (Phenom‐World,
Eindhoven, The Netherlands). Adjustable manual pipettes from
Sartorius AG (Göttingen, Germany) were used. Digital Vortex Mixer and
Thermal Shake Touch were purchased from VWR (Randor, PA, USA).
Concentrator plus was from Eppendorf AG (Hamburg, Germany). The
UltiMate 3000 RS liquid chromatography system (UHPLC; Dionex,
Sunnyvale, CA, USA) equipped with a Hypersil Gold Phenyl column
(50 mm × 2.1 mm I.D., particles 1.9 μm; Thermo Scientific, Bermen,
Germany) was used for chromatographic analyses. Chromatograph was
coupled to a mass spectrometer (MS) equipped with electrospray ioni-
zation source (ESI) and MicroTOF-Q II time of flight analyzer (TOF)
(Bruker, Bermen, Germany). MS detection was performed based on
signal intensity with positive ion [M+H]+ mode, covering the range of
target analytes values (ca. 237–337m/z). Table 1. reports about ad-
justed MS parameters. The data acquisition and processing were per-
formed using Chromeleon 6.8 (Dionex), HyStar 3.2, MicrTOFcontrol
and Compass DataAnalysis software (Bruker), respectively. In order to
obtain extracted ion chromatograms, expected masses of ions of all
analytes, [M+H]+, were calculated using IsotopePattern software
(Bruker).
2.2. The LC-MS method conditioning
The MS settings, gradient program, and mobile phase were chosen
on previously done research for psychoactive substances [15,16]. The
eluent A (0.1% formic acid in ultrapure water) and eluent B (acetoni-
trile) were pumped at a flow rate of 0.3 mL/min at 35 °C. The gradient
program was performed as follows. First, mobile phase B increase from
15% (0.0min) to 40% (4min). Next, the content of 40% was used for
3min (4.0–7.0min) and then increase from 40% (7min) to 70%
(10min). Subsequently, the mobile phase B content was decreased from
70% (10min) to 15% (12.5min) and held for 4.5min (12.5–17.0 min)
to equilibrate the column for the next injection. The injection volume
was 5 μL.
The choice of those parameters allowed to obtain all analyzed
substances in less than 10min. Fig. 1. present extracted ion chroma-
tograms of blank and spiked blood with 25 analyzed psychotropic
substances (100 ng/mL).
2.3. Sample collection and preparation
Drug-free human blood samples as a surrogate matrix were pro-
vided by unknown examined donors from Blood Donation Center in
Krakow, Poland. Case samples (bone marrow aspirates) were provided
by courtesy of the Forensic Medicine Unit at the Department of Forensic
Medicine of the Wroclaw Medical University (according to the
Bioethical Commission Approval no 1072.6120.303.2018). All samples
were stored frozen until use at the temperature of −20 °C. Blood and
bone marrow aspirate were prepared 24 h prior to the analyses by
spiked them with a known amount of internal standards solution and
drugs solution in case of creation calibration curve using drug-free
blood samples. Spiked samples were stored at the temperature of 4 °C
until the extraction process. List of analytes with physical and chemical
properties were presented in Table 2.
2.4. Optimization of DI-SPME
2.4.1. Sample volume
For toxicological analysis techniques requiring small sample vo-
lumes are favored but considering the SPME technique, some limita-
tions are encountered. The first condition is to ensure complete cov-
erage of coated sorbent, while the second is associated with the
mechanism of extraction process. It is based on an equilibrium process,
so the volume of the sample significantly effects this process. Using
smaller sample volumes results in lower quantities of analytes and, in
consequence, smaller quantities of the analytes can be extracted.
Therefore, the process of adsorption must occur efficiently as well as the
desorption process [17].
2.4.2. Adsorption time
To establish the time of reaching the equilibrium the analyses of
amount extracted versus adsorption time have been made. The ex-
tractions were performed with the use of 200 μL of blood placed in the
inserts, located internally in 1.5mL HPLC vials with the agitation of
2200 rpm. To the desorption solution, IS solution was added to check
the ratio of amount of analyte which was extracted to the initial amount
Table 1
Adjusted mass spectrometer parameters.
Equipment Parameter [unit] Value for MS coupled with LC-MS
ESI ionization mode positive
capillary voltage [kV] 4.5
nebulizer pressure [bar] 2.5
dry gas flow [L/min] 5.5
dry gas temperature [°C] 200
MS-TOF mass range 50–800
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Fig. 1. Extracted ion chromatograms of blank and spiked blood sample. Peak assignment: (1) VEN; (2) ZOL; (3) BRO; (4) MID; (5) CBZ; (6) TETRA; (7) CIT; (8)
NITRA; (9) NORD; (10) EST; (11) LOR; (12) DESI; (13) PAROX; (14) IMI; (15) CLO; (16) NORT; (17) ALP; (18) AMI; (19) TEM; (20) FLUN; (21) FLUOX; (22) CLOR;
(23) LORM; (24) DIA; (25) PRA.
Table 2
List of analytes and their physical and chemical properties (active metabolites, therapeutic and toxic range concentration, pKa, logP, [M+H]+, protein binding and
retention time).











0.005–0.05 (s) 0.1–0.4 (s) 2.4 2.12 309.0901 70–80 6.35
BRO C14H10N3OBr 3-hydroxybromazepam 0.08–0.15 (p) 0.3–0.4 (s) 2.9; 11.0 2.05 316.0080 70 4.45
CLO C15H10N3O3Cl 7-aminoclonazepam 0.02–0.07 (p) >0.1 (p) 1.5; 10.50 2.41 316.0483 86 6.29
CLOR C16H11N2O3Cl nordazepam, oxazepam 0.02–0.8 (s) 1.5–2 (b) 3.5; 12.50 2.05 337.0350 91 6.80
DIA C16H13N2OCl nordazepam, oxazepam,
temazepam
0.1–2.5 (p) 3–5 (b) 3.5 2.8 285.0789 89–99 6.93
EST C16H11N4Cl 4-hydroxyestazolam 0.055–0.2 (s) no information 12.33 4.70 295.0745 93 6.10
FLUN C16H12N3O3F desmethylflunitrazepam 0.005–0.015 (s) > 0.045 (b) 1.80 2.10 314.0935 77–80 6.61
LOR C15H10N2O2Cl2 -* 0.05–0.25 (p) 0.3–0.6 (p) 1.3; 11.50 2.40 321.0192 90 6.10
LORM C16H12N2O2Cl2 lorazepam 0.001–0.025 (s) no information 11.60 2.2 335.0348 90 6.80
MID C18H13N3FCl 1-hydroxymethyl-midazolam 0.08–0.25 (s) 1–2.5 (b) 6.20 4.30 326.0855 95–98 5.08
NITRA C15H11N3O3 -* 0.03–0.07 (s) 0.2–3 (b) 3.2; 10.80 2.25 282.0873 85–88 5.84
NORD C15H11N2OCl oxazepam 0.02–0.8 (s) 1.5–2 (b) 3.5; 12.00 2.93 271.0633 97 5.84
PRA C19H17N2OCl nordazepam, oxazepam 0.2–0.7 (s) 1–2 (b) 2.70 3.70 325.1102 97 9.09
TEM C16H13N2O2Cl oxazepam 0.03–0.9 (s) > 1 (s) 1.60 2.20 301.0738 96 6.61
TETR C16H17N2OCl diazepam, nordazepam 0.05–0.6 (p) no information 4.30 3.20 289.1102 30–70 5.53
Sedatives/hypnotics
ZOL C19H21N3O -* 0.08–0.15 (s) > 0.5 (s) 6.2 3.85 308.1757 92 3.87
Anticonvulsants
CBZ C15H12N2O 10,11-epoxide 4–12 (s) > 15 (p) 13.94 2.45 237.1102 75 5.40









AMI C20H23N nortriptyline 0.1–0.2 (p) >0.3 (p) 9.40 4.94 278.1903 91–97 6.42
DESI C18H22N2 2-hydroxydesipramine 0.007–0.13 (p) >0.4 (p) 10.4 4.90 267.1856 70–90 6.10
IMI C19H24N2 desipramine, hydroxyimipramine,
2-hydroxydesipramine
0.1–0.3 (p) >0.50 (p) 9.53 4.47 281.2012 85–95 6.23




0.2–0.75 (s) 1–1.5 (b) 10.10 2.9 278.2115 30 3.81
CIT C20H21N2OF desmethylcitalopram 0.02–0.20 (p) Lethal conc. 0.5 9.50 3.74 325.1710 50 5.65
FLUOX C17H18NOF3 norfluoxetine 0.15–0.5 (s) 1.3–6.8 (b) 4.05 4.05 310.1413 95 6.67
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of analyte. The chosen adsorption times were 1, 5, 10, 15, 20, 30, 60
and 90min. For each time 3 repetitions have been made.
The determination of the concentration of analytes can be also
performed by using pre-equilibrium times with very short sampling
times, but this approach requires kinetic on-fibre standardization as a
kinetic calibration method [18].
2.4.3. Post-adsorption washing
In the DI-SPME technique fiber is exposed directly to a sample. In
case of biological samples like blood or bone marrow aspirate, residues
of biological materials are deposited on the fiber coating. Omission of
the rinsing step process which follows the adsorption results in clot
formation, due to the composition of organic desorption solution. For
this reason, it was decided to introduce an additional process such as
washing in ultrapure water and mechanical purification.
2.4.4. Desorption time
Investigation of desorption time was performed for desorption
times: 10, 30, 45 and 60min. The desorption solution was adjusted to
the type of the fiber coating and analytes [19]. The desorption process
was carried out with the use of 200 μL of desorption solution of
ACN:MeOH:0.1%HCOOH (2:2:1, v/v/v) placed in the inserts, located
internally in 1.5mL HPLC vials with the agitation of 2200 rpm.
2.5. Validation
Validation parameters were calculated according to standard prac-
tices for method validation by Scientific Working Group for Forensic
Toxicology (SWGTOX) [20], Bioanalytical Method Validation Guideline
for Industry (FDA) [21], strategy presented by Matuszewski [22] and
previous analyses done by Wietecha-Posłuszny et al. [15]. For devel-
oped method parameters as linearity, limit of detection, limit of
quantification, precision and matrix effect were evaluated. In validation
process only blood samples were used as the best a surrogate matrix for
BMA.
The first step of validation was evaluation of the linearity of the
examined range. For the calibration process, the Interpolative Internal
Standard Method (IISM) was applied [23]. The calibration curves were
constructed by linear regression of area ratios of analytes peak to the IS
peaks with the nominal concentrations (IA/IIS). The concentrations of
analytes were tested within the therapeutic and toxic range of
30–300 ng/mL (30, 50, 100, 150, 200, 300 ng/mL). Slope and R2 values
were calculated and reported for three different runs. The limit of de-
tection (LOD) and the limit of quantification (LOQ) were calculated on
the basis of standard deviation of the y-intercept (Sy) for the lowest











Precision was calculated at three concentration levels (50, 150,
300 ng/mL) over the calibration range for four replicates for intraday
precision per concentration (n=4) and interday precision per twelve
replicates (n=12) in three separate analytical runs per day. The mean
(Avgc) and standard deviation (S) of the response were calculated using
Equation (3) for each concentration to determine the precision as a
coefficient of variation (CV). Results were evaluated according to the
criteria that CV should not exceed 15%, with the exception of the LOQ,





Fig. 2. Adsorption time plots for DIA, ZOL, NORT and MID.
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The examination of ‘absolute’ ME was carried out by analysis of four
different materials of various origins and in each case preparation of
two measuring series. The first series (I) was prepared in accordance
with the protocol for SPME, extraction was performed in biological
material without analytes and later addition of known, appropriate
amount of mix of analytes in the solution of the mobile phase. The
second series (II) was prepared by addition of appropriate amount of
mix of analytes to the mobile phase. The ‘absolute’ matrix effect was
calculated using Equation (4), as a ratio of analytical signal obtained for






Bone marrow aspirates from 8 forensic cases (26/17, 95/17, 649/
15, 161/17, 266/17, 396/17, 476/16, 412/16) were analyzed. The
post-mortem samples were originated from the Forensic Medicine Unit
at the Department of Forensic Medicine of the Wroclaw Medical
University and were classified as samples that may contain psycho-
tropic drugs.
3. Results and discussion
3.1. Optimization
3.1.1. Sample volume
Considering limited availability of sample, the adsorption was
Fig. 3. SEM photographs of the fibers A (brand-new), B (after post-adsorption washing) in at magnification of 500 (1), 2000 (2) and 4000 (3) times.
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performed with the use of 200 μL. Sample solution was placed in 200 μL
inserts, located internally in 1.5mL HPLC vials. The optimized volume
of the sample was chosen so as to cover up the 1.5 cm coating of SPME
fiber.
3.1.2. Adsorption time
On the basis of the obtained signals for each time, adsorption curves
were determined and the chosen plots were collected in Fig. 2. Equili-
brium level on time was found to stabilize for different analytes in
different times. The differences occur due to the diverse character of the
analytes, a wide range of masses and various distribution constants (see
Table 2). The equilibrium for some analytes of interest was found to
reach equilibrium already after 30min (NORT and MID) to even 60min
(DIA and ZOL), but choosing the shorter times would reduce the
amount of extracted analyte and in consequence have an impact on the
limit of detection. To ensure that equilibrium for all the analytes is
reached the time of adsorption at room temperature was chosen for
60min.
Fig. 4. Desorption time plots for PAROX, ALP, BRO and CLO.
Fig. 5. Final procedure of DI-SPME method of sample preparation and fiber cleaning.
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3.1.3. Post-adsorption washing
Desorption process which follows the adsorption was carried out in
an organic solvent what resulted in the formation of a clot, which was
difficult to remove. Due to this post-adsorption coating purification was
introduced between adsorption and desorption process to clear out in-
terfering components from the coating of the fiber and avoid fouling of
the coating. The post-adsorption purification was implemented after
adsorption process and it consisted of two steps. The first step was to:
wipe coating with dust-free materials, in case to remove formed clots,
and then the second step was: the washing in the ultrapure water to
providing to remove loosely bound residual of biological samples. The
time of the washing step was selected on the basis of visual and mi-
croscopic assessment and last 5 s (with vortex agitation 5000 rpm).
The fibers were monitored with the use of Scanning Electron
Microscope to control the usage of the fiber and process of cleaning. In
Fig. 3 micrography's of brand-new fiber (A) and used fiber (B) which
have been used for all carried out experiments are presented. On the
used fibers, in minor parts, there are observed networks, which are
probably the networks of the proteins, but the extent of the networks is
not extensive and didn't affect the process of extraction, what proved
the values of precision. It just indicates the need of fiber usage mon-
itoring.
3.1.4. Desorption time
Equilibrium desorption time like in the adsorption process was ob-
tained based on adsorption signal-times curves, several of which are
presented in Fig. 4.
Desorption of analytes from the fiber is very rapid. As presented on
the plots for most analytes, desorption maintained on the same level
from 10min to 60min (ALP, BRO, and CLO). To provide complete
desorption for most of the analytes the chosen desorption time in room
temperature was 30min.
3.1.5. The developed extraction procedure
This DI-SPME procedure is designed for the direct sampling of 25
psychotropic drugs from biological matrices like blood and BMA. The
new procedure eliminates the need of protein precipitation, cen-
trifugation or any other sample preparation. By reducing the number of
steps, the time of the whole analysis is shortened, and the only lim-
itation for a number of samples, which are analyzed, is a number of
available fibers and number of places in the shaking plate. The method
Table 3
Summary of the validation parameters for DI-SPME/LC-MS method.
Parameter ALP AMI BRO CBZ CIT CLO CLOR DESI DIA EST FLU FLUOX IMI
Linearity [ng/mL] LOQ – 300
a 0.0107 0.0162 0.0225 0.0075 0.1030 0.0049 0.0081 0.0364 0.0095 0.0058 0.0249 0.0035 0.0118
b 0.0626 −0.1862 −0.0921 −0.0460 1.4159 0.0195 −0.0082 −0.1413 −0.0403 −0.1220 −0.6404 −0.0348 −0.2087
R2 0.9970 0.9987 0.9975 0.9957 0.9991 0.9934 0.9957 0.9954 0.9978 0.9963 0.9968 0.9963 0.9975
LOD [ng/mL] 1.87 2.98 2.35 4.10 9.98 10.45 7.01 9.49 7.86 4.90 2.96 5.80 3.08
LOQ [ng/mL] 5.60 8.95 7.06 12.30 29.95 31.35 21.02 28.48 23.58 14.69 8.88 17.40 9.23
precision, 50 [ng/mL] CV
[%]
interday 3.07 2.09 0.78 3.49 8.55 9.09 10.54 6.75 4.99 2.47 3.54 3.15 3.80
intraday 10.72 8.82 7.95 7.80 11.4 9.27 7.09 10.78 10.09 6.39 6.51 8.01 11.00
precision, 150 [ng/mL]
CV [%]
interday 5.08 9.68 5.85 4.32 4.29 12.59 2.38 1.84 2.45 3.57 2.85 1.47 9.40
intraday 4.15 5.15 5.04 5.43 7.05 4.75 6.75 5.18 7.24 8.46 6.53 3.85 6.36
precision, 300 [ng/mL]
CV [%]
interday 14.85 14.51 0.38 6.11 6.05 9.36 2.98 4.24 1.57 14.21 12.92 6.39 10.72
intraday 8.98 7.14 2.58 3.72 3.64 2.27 0.98 5.62 4.66 6.64 3.22 2.29 5.80
‘absolute’ matrix effect,
ME [%]
50 103.57 95.19 105.08 102.76 119.72 108.31 100.45 105.61 94.42 91.28 105.11 99.90 91.82
150 91.29 100.10 107.61 102.08 107.18 109.24 110.96 101.63 95.88 100.19 92.51 106.01 107.64
300 89.01 95.64 94.19 105.28 106.48 99.56 97.38 103.51 92.36 100.02 90.77 104.77 102.41
Parameter LOR LORM MID NITR NORD NORT PAROX PRA TEM TETR VEN ZOL
Linearity [ng/mL] LOQ – 300
a 0.0092 0.0087 0.0110 0.0150 0.0171 0.0088 0.0064 0.0113 0.0125 0.0074 0.0139 0.0115
b −0.0091 0.1435 −0.0601 −0.0693 −0.0619 0.0550 0.0532 0.0819 −0.3801 0.0556 −0.1388 −0.1045
R2 0.9961 0.9979 0.9968 0.9962 0.9996 0.9952 0.9960 0.9957 0.9996 0.9985 0.9976 0.9978
LOD [ng/mL] 10.14 10.21 7.1 3.85 3.14 4.93 5.34 5.74 14.27 4.18 5.46 1.98
LOQ [ng/mL] 30.41 30.64 21.31 11.56 9.41 14.80 16.02 17.22 42.80 12.55 16.39 5.93
precision, 50 [ng/mL] CV [%] interday 8.60 5.11 2.48 4.12 1.07 4.93 3.32 3.55 3.66 4.52 1.63 0.48
intraday 11.86 7.98 10.64 8.22 7.79 11.30 9.50 6.41 6.59 6.92 5.35 4.78
precision, 150 [ng/mL] CV [%] interday 5.13 2.14 5.02 3.10 2.98 3.44 10.34 5.30 7.76 4.39 1.62 0.84
intraday 5.93 5.66 5.71 6.29 6.75 5.53 6.08 5.30 7.11 6.91 6.35 4.39
precision, 300 [ng/mL] CV [%] interday 12.49 11.67 6.14 5.65 9.67 3.83 8.63 7.53 4.15 4.31 4.36 3.73
intraday 7.72 5.86 4.79 4.72 4.80 2.26 5.38 4.23 7.17 3.69 2.90 2.77
‘absolute’ matrix effect, ME [%] 50 98.27 109.25 110.48 147.01 112.52 90.28 113.76 113.26 112.68 109.00 111.07 114.27
150 104.56 101.78 107.08 149.64 98.48 91.77 100.32 112.14 101.01 112.31 105.95 100.12
300 94.48 97.23 97.07 145.09 103.00 93.77 98.64 105.93 97.62 97.64 100.95 105.71
Interday (n=4), intraday n= 12.
Table 4
Drugs and metabolites found in analyzed case samples (BMA) using DI-SPME-
LC-TOFMS method.
Case No. Detected drugs Concentration and SD [ng/mL]
26/17 IMI 38.78 ± 6.12
BRO 37.18 ± 4.14
95/17 IMI 27.61 ± 3.70
649/15 ALP 415.86 ± 7.21
IMI 44.31 ± 8.47
BRO 147.51 ± 24.39
ZOL 44.20 ± 1.35
PAROX 26.33 ± 2.32
VEN 20.10 ± 2.23
161/17 AMI 25.60 ± 1.29
IMI 65.79 ± 4.81
PAROX 19.81 ± 0.80
NORT 23.50 ± 1.63
VEN 16.63 ± 1.44
266/17 IMI 44.27 ± 0.88
396/17 IMI 35.76 ± 1.76
BRO 51.57 ± 6.06
DIA < LOQ
476/16 IMI 36.77 ± 1.6
412/16 IMI 22.45 ± 2.48
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may in this way increase sample throughput because many fibers could
be used simultaneously.
The first step of the procedure was conditioning of the fibers. For
analysis of psychotropic drugs SPME LC Probe 45 μm C18-Silica was
chosen. The composition of conditioning solution was recommended by
the producer in the data sheet enclosed to the product. Conditioning of
the coatings took place in the 1.5 mL of a solution of MeOH:H2O (1:1,
v/v) with continuous shaking of 2200 rpm. Conditioning of the fibers
lasted 45min. The next step was adsorption. It was performed with the
use of 200 μL of sample placed in the inserts, located internally in
1.5 mL HPLC vials with the agitation of 2200 rpm. After adsorption
purification was followed. The fiber was wiped with a dust-free tissue
than washed in the ultrapure water for 5 s with the vortex agitation
5000 rpm. Desorption was carried out with the use of 200 μL of deso-
rption solution of ACN:MeOH:0.1%HCOOH (2:2:1, v/v/v) placed in the
inserts, located internally in 1.5 mL HPLC vials with the agitation of
2200 rpm. Desorption time was fixed for 30min. After desorption fibers
were placed in the cleaning solution (MeOH:H2O:isopropanol, 2:2:1,v/
v/v). The desorption solutions were evaporated with use of a vacuum
evaporator at a temperature of 45 °C. Afterwards, 50 μL of the mobile
phase (0.1% HCOOH) was added and vortexed in the speed of
2500 rpm. Samples prepared in accordance with this procedure (Fig. 5)
were analyzed with the use of LC-TOF MS system in order to method
validation and next application in case samples measurements.
3.2. Validation
Developed method DI-SPME/LC-TOFMS was validated. Parameters
like linearity, limit of detection LOD, limit of quantification LOQ, pre-
cision and matrix effect were evaluated for all analytes of interest. The
obtained parameters were summarized in Table 3.
Prepared blood samples that were analyzed were spiked with ana-
lytes 24 h before analyses on 3 levels of concentrations: low 50 ng/mL,
medium 150 ng/mL and high 300 ng/mL. As internal standards ade-
quate deuterated analytes were used at a concentration of 100 ng/mL.
For analysis of linearity for each analyte six-point calibration curves
were prepared. Calibration curves were prepared with the use of blood,
which were spiked with a known amount of mix of analytes and their
deuterated analogues obtaining concentrations: 30, 50, 100, 150, 200,
and 300 ng/mL. Linearity was determined in the range from LOQ for
each analyte to the highest concentration of calibrator, equal to 300 ng/
mL. The parameter of the coefficient of determination show agreement
with acceptance criteria of R2 > 0.995, and only for one analyte, CLO,
coefficient of variation is below this criterion. For 24 analytes linear
model was obtained. The calculated LOQs enable determination of 16
analytes in the range of both therapeutic and toxic concentrations (see
Table 2), which creates opportunities for clinical exploitation and ap-
plication [24]. For drugs CIT, CLO, CLOR, DESI, FLU, LORM PAROX,
PRA, TEM and TETR determination of low therapeutic concentrations is
not possible, in this case only the middle therapeutic level is possible to
determine.
The obtained LOD and LOQ for analytes of interest fall respectively
within the scope of 1.87–14.27 ng/mL and 5.60–42.80 ng/mL. These
values for all drugs enable analysis of chosen drugs at a toxic level and
also allow the method to be extended to analysis many drugs of interest
at the therapeutic level.
Calculated values of precision (CV) for intraday analyses do not
exceed 14.51% (AMI), while the variabilities of analyses carried out
interday do not exceed 11.86% (LOR). For all analytes, obtained pre-
cision meets the established criteria, what is a very satisfactory result.
On this basis, it was concluded that the method is characterized by good
repeatability and reproducibility.
Obtained ‘absolute’ ME results for 24 analytes meets the established
criteria. The one which exceeds the set range is NITR, where strong ion
enhancement is observed. It can be seen that the influence of the matrix
for the lowest concentration is the highest for almost all analytes. The
Fig. 6. Extracted ion chromatograms for 26/17, 161/17 and 266/17 case samples.
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experience carried out shows that for most analytes there is no sig-
nificant influence of ME observed. The accuracy of the method wasn't
evaluated due to the lack of adequate reference material.
3.3. Post-mortem case samples
The DI-SPME/LC-TOFMS method can be used successfully for blood
samples (see Paragraph 3.2 Validation) and bone marrow aspirates
samples 26/17, 95/17, 649/15, 161/17, 266/17, 396/17, 476/16,
412/16 presented in this section. For analyzed cases, from one to six
drugs from all analyzed drug groups were determined. The obtained
results were presented in Table 4. The standard deviations of con-
centrations were determined for each sample and it was usually less
than 15%. In Fig. 6 extracted ion chromatograms for selected case
samples are shown. In analyses which were carried out, 9 different
drugs were determined: BRO, IMI, ALP, ZOL, PAROX, VEN, AMI, NORT
and DIA. In most of the samples, IMI was determined, which may mean
that although it was withdrawn from treatment, drug poisoning is still
used, and unfortunately very popular. The metabolite of IMI is DESI
which was also the subject of this research, but it was not detected
together with IMI – probably because of low content in the samples. In
the case of 161/17 sample, AMI was detected with its metabolite NORT.
One drug, DIA, were detected only because its determined value was
below the LOQ parameter.
Due to the fact that BMA is an alternative material, it is difficult to
classify obtained concentrations as therapeutic or toxic.
4. Conclusions
The present study showed that DI-SPME/LC-TOFMS method is rapid
and allows to simplify the labor-intensive and usually complicated
process of isolating analytes from the complex biological matrix.
Moreover, this method is suitable for quantitative analyses and SPME
fibers may be used repeatedly, as no fiber damage or ‘fouling’ is ob-
served, with the applied cleaning and conditioning.
The DI-SPME/LC-TOFMS method was developed and validated on
spiked blood samples and used in determination of 25 psychotropic
drugs from post-mortem BMA samples.
In the future, researches could be focused on the enlargement of the
number of analytes and also on prospecting if there is any correlation
between concentrations of analytes in biological materials, in this case
between blood and BMA.
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